Open AccessPeriorbital skin cancers subjected to mTHPC‐photodynamic therapy: A prospective study
Author(s) -
Hamdoon Zaid,
Jerjes Waseem,
Hopper Colin
Publication year - 2020
Publication title -
skin research and technology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.521
H-Index - 69
eISSN - 1600-0846
pISSN - 0909-752X
DOI - 10.1111/srt.12806
Subject(s) - photodynamic therapy , medicine , dermatology , basal cell carcinoma , basal cell , prospective cohort study , visual analogue scale , lesion , disfigurement , surgery , pathology , chemistry , organic chemistry
Photodynamic therapy (PDT) is a relatively new method of treating skin cancers. This prospective study highlights the use of PDT in the management of basal cell carcinomas (BCCs) and T1N0 cutaneous squamous cell carcinomas (SCCs) involving the periorbital area. Materials and methods Surface illumination PDT was offered under local anaesthesia. mTHPC was administered intravenously. A single‐channel 652 nm diode laser was used for illumination, and light was delivered at 20 J/cm 2 per site. Lesion response evaluation was carried out according to response evaluation criteria in solid tumours (RECIST). Results After the first round of treatment, all cutaneous T1N0 SCC patients had complete response (CR) and continued to be in remission until last clinic review. For BCC patients, 12/14 patients had CR. The two remaining patients underwent a second round of treatment and also achieved a CR. All BCC patients were in remission at the last clinic review. Using visual analogue scale (VAS), 15 patients reported that this treatment gave them “excellent” cosmetic outcome (VAS 9‐10). Conclusion Photodynamic therapy achieved high efficacy in the treatment of periorbital BCCs and cutaneous SCCs with greatly reduced morbidity and disfigurement.